WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Table des matières
Ouvrir ce répertoire et afficher son contenuRegulatory decisions
Ouvrir ce répertoire et afficher son contenuDrug surveillance
Fermer ce répertoireNew developments
Afficher le documentFomepizole - approved as an antidote in ethylene glycol poisoning: USA
Afficher le documentInfliximab - approved for Crohn’s disease: USA
Afficher le documentLeflunomide - oral treatment approved for active rheumatoid arthritis: USA
Afficher le documentLepirudin - approved for heparin-associated thrombocytopenia: UK
Afficher le documentOral contraceptives - approved for emergency use: USA
Afficher le documentRotavirus vaccine - approved to help prevent rotaviral disease: USA
Afficher le documentThalidomide - approved for use in leprosy: USA
Afficher le documentNew indications
Afficher le documentNew formulations
Afficher le documentNewly approved products
Ouvrir ce répertoire et afficher son contenuMedical devices
Ouvrir ce répertoire et afficher son contenuGeneral information
Ouvrir ce répertoire et afficher son contenuMedication errors
Ouvrir ce répertoire et afficher son contenuVeterinary medicine
 

Fomepizole - approved as an antidote in ethylene glycol poisoning: USA

United States of America. The Food and Drug Administration has approved fomepizole (Antizol: Orphan Medical) as an antidote for ethylene glycol poisoning and in cases of suspected ethylene glycol ingestion.

Ethylene glycol is a sweet-tasting compound that has wide commercial use as a preservative, antifreeze, coolant and glycerol substitute. It is commonly used in attempted suicides and ingestion can be fatal. Ethylene glycol has intoxicating properties similar to those of alcohol, and its metabolites cause central nervous system, renal and cardiopulmonary dysfunction together with severe metabolic acidosis.

The use of fomepizole is recommended if ethylene glycol serum levels are above 20 mg/dl or if ingestion of ethylene glycol is suspected. In cases where ethylene glycol levels are equal to or above 50 mg/dl, or when the patient has renal failure or worsening metabolic acidosis, haemodialysis should also be considered. Haemodialysis removes fomepizole, therefore doses must be given more frequently during haemodialysis.

References: FDA Orphan Products approved for Marketing, December 1997 & April 1998, in: INFORx-MED Vol. 16, No. 7, July 1998, Medicines Information Centre, Cape Town, South Africa.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013